Trial Profile
CODEX:Collection of Aflibercept Data in Routine Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Branch retinal vein occlusion; Central retinal vein occlusion; Diabetic macular oedema; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms CODEX
- Sponsors Bayer
- 03 Jul 2018 Status changed from recruiting to completed.
- 04 Jun 2018 Planned End Date changed from 30 May 2018 to 14 Jun 2018.
- 04 Jun 2018 Planned primary completion date changed from 30 May 2018 to 14 Jun 2018.